CompletedEarly Phase 1NCT04971200

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Studying Hypopigmentation of the skin

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Premier Specialists, Australia
Principal Investigator: Dedee Murrell, MD
University of New South Wales
Intervention: Tildrakizumab(drug)
Enrollment: 12 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2024

Study locations (1)

Premier Specialists Pty Ltd, Sydney, New South Wales, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04971200 on ClinicalTrials.gov

Other trials for Hypopigmentation of the skin

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06908889
Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome
Centre Hospitalier Universitaire de Nice

See all trials for Hypopigmentation of the skin →

← Back to all trials